Table 1:

Demographic and clinical summary of patients treated on ADVL1712

	Part
	PK (N=6)	Stratum 1 (N=6)	Total (N=12)
Age
N	6	6	12
Median	16.5	9.5	13.0
Range	1.0, 21.0	3.0, 17.0	1.0, 21.0
Gender, n (%)
Male	2 (33%)	3 (50%)	5 (42%)
Female	4 (67%)	3 (50%)	7 (58%)
Race, n (%)
White	5 (83%)	2 (33%)	7 (58%)
Multiple Races	0 (0%)	2 (33%)	2 (17%)
Unknown	1 (17%)	2 (33%)	3 (25%)
Ethnicity, n (%)
Hispanic or Latino	3 (50%)	1 (17%)	4 (33%)
Not Hispanic or Latino	3 (50%)	5 (83%)	8 (67%)
Diagnosis Disease, n (%)
Acute monocytic leukemia	1 (17%)	0 (0%)	1 (8%)
Acute myeloid leukemia, NOS	4 (67%)	6 (100%)	10 (84%)
Therapy-related acute myeloid leukemia, NOS	1 (17%)	0 (0%)	1 (8%)
Prior Chemotherapy
N	6	6	12
Median	2.0	3.0	2.0
Range	1.0, 4.0	2.0, 5.0	1.0, 5.0
Prior Radiation
N		1	1
Median		1.0	1.0
Range		1.0, 1.0	1.0, 1.0
Stem Cell Transplant, n (%)
No	5 (83%)	4 (67%)	9 (75%)
Yes	1 (17%)	2 (33%)	3 (25%)
5% blasts in the bone marrow, n (%)
<=5% disease Baseline	1 (17%)	1 (17%)	2 (17%)
> 5% disease Baseline	5 (83%)	5 (83%)	10 (83%)
Response Status, n (%)
Complete Remission	2 (33%)	1 (17%)	3 (25%)
Treatment Failure	4 (67%)	5* (83%)	9 (75%)

^*2 patients didn’t have marrow evaluation performed due to clinical status but did have circulating peripheral blasts at the time of evaluation and were determined to best classified as TF.